Researchers continue to excited about this new drug, a novel dual agonist showing remarkable data in early trials for size reduction . It functions by modulating two systems: GLP-1 and GIP, which , when engaged , assist regulate appetite and enhance energy expenditure . Initial observations demonstrate substantial body reduction and possible improv